Therefore, we next aimed to assess the efficacy of the resveratrol derivatives in inhibiting NFκB activity by utilizing a dual-luciferase reporter assay for NFκB target gene (IL-6) in two colon cancer cell lines (HCT-116 and SW-480) and a normal mouse intestinal cell line (ModeK). Here, NFKB1 is linked to colonic neoplasm.